Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Products under Development by Stage of Development | 7 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Products under Development by Therapy Area | 8 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Products under Development by Indication | 9 | 2 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Products under Development by Companies | 13 | 3 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Companies Involved in Therapeutics Development | 22 | 6 |
| AB Science SA | 22 | 2 |
| AstraZeneca Plc | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| ValiRx Plc | 26 | 1 |
| Zen-Bio, Inc. | 27 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Drug Profiles | 28 | 24 |
| dasatinib Drug Profile | 28 | 3 |
| masitinib Drug Profile | 31 | 14 |
| saracatinib difumarate Drug Profile | 45 | 2 |
| Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders Drug Profile | 47 | 1 |
| VAL-201 Drug Profile | 48 | 4 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Dormant Projects | 52 | 2 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Discontinued Products | 54 | 1 |
| Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Featured News &Press Releases | 55 | 16 |
| Jul 11, 2016: AB Science Announces The Publication In The Journal Of Neuroinflammation Of Preclinical Data Showing Neuroprotective Effect Of Masitinib In Amyotrophic Lateral Sclerosis | 55 | 1 |
| Jul 11, 2016: FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis | 56 | 1 |
| Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) | 56 | 1 |
| Jun 29, 2016: Leukaemia drug shows potential for rarer type of ovarian cancer | 57 | 1 |
| Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association | 58 | 1 |
| Jun 07, 2016: ValiRx announced Quarterly Update on Clinical Development of VAL201 | 58 | 1 |
| Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization | 59 | 1 |
| May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association | 60 | 1 |
| May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis | 61 | 1 |
| Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) | 62 | 3 |
| Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, | 65 | 1 |
| Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis | 66 | 2 |
| Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR | 68 | 1 |
| Mar 10, 2016: AB Science: New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases | 68 | 1 |
| Mar 02, 2016: AB Science will present new preclinical and clinical data at the International Symposium on Advances in Alzheimer Therapy (ATT 2016) | 69 | 2 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |